Interactive dashboard visualizing Health-Related Quality of Life (HRQOL) outcomes from the MONALEESA-3 study comparing Ribociclib + Fulvestrant vs Placebo + Fulvestrant in advanced breast cancer.
Study Design & Arms
Randomized comparison of Ribociclib vs Placebo (plus Fulvestrant backbone).
Baseline Scores
Comparison of Global Health Status and Pain scores at study entry. Higher Global Health is better; Lower Pain is better.
Longitudinal Change: Global Health Status
Change in Global Health Status/QOL scores from Baseline to Cycle 15 Day 1.
Time to Deterioration (Hazard Ratios)
Hazard Ratios < 1.0 indicate Ribociclib delays deterioration compared to Placebo.
Metric Overview Heatmap
Overview of mean values across all collected metrics and groups.
Key Takeaways
Summary of findings based on extracted evidence.
Positive Outcomes
Study Context
Appendix: Raw Data
| Metric ID | Metric Name | Group | Value | Source |
|---|